Helmedix Lands Seed Funding to Back Helminth Peptide R&D
By Nuala Moran
Wednesday, March 20, 2013
Start-up Helmedix Pty Ltd. has raised A$1.25 million (US$1.29 million) in seed funding, providing a springboard to the commercialization of molecules based on immune-modulating peptides used by helminth parasites to suppress the immune response of their hosts.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.